StemRim is a leading biotechnology company devoted to the development of regenerative medicine and gene therapy. Their primary focus is on innovative therapies such as regenerative induction medicine®. StemRim has a strong commitment to advancing healthcare by addressing the limitations of conventional regenerative medicine.

StemRim's advantage lies in their expertise in regenerative induction medicine®, which sets them apart from traditional regenerative therapies. They offer a wide range of products and services in various disease areas and have a robust development pipeline. Their offerings include a therapeutic self-cell collection device for regenerative induction medicine®, as well as stem cell gene therapy.

StemRim continuously contributes to scientific research and academia by publishing papers and participating in academic presentations. StemRim is dedicated to transparency and sustainability and keeps their shareholders and investors well-informed. The company also provides financial highlights, an extensive library of investor information, and an IR schedule.

Located in Osaka, Japan, StemRim welcomes inquiries via their online contact form or by phone during their business hours. As pioneers in regenerative induction medicine®, StemRim has established trademarks for regenerative induction, regenerative induction medicine, regenerative induction medical science, and regenerative induction therapy